Indatuximab ravtansine
Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities[1].
Product Specifications
CAS Number
1238517-16-2
Product Name Alternative
BT-062; nBT062-DM4
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; Bacterial
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Anti-infection
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/indatuximab-ravtansine.html
Purity
99.09
Solubility
10 mM in DMSO
Smiles
[Indatuximabravtansine]
References & Citations
[1]Kurt Schönfeld, et al. Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. J Hematol Oncol. 2017 Jan 11;10 (1) :13.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog